Scholarlink

Background <p>The united airway diseases (UADs), exemplified by allergic rhinitis and asthma, cause significant morbidity. Although conventional pharmacotherapy provides symptomatic relief, recent evidence has indicated that cellular therapy, such as stem cell-derived exosomes, might offer therapeutic advantages throughout the entire respiratory tract.</p> Objectives <p>The present study intends to demonstrate the effect and explore the mechanism of a novel pharmaco-exosomal immunotherapy, i.e., mesenchymal stem cells-derived exosomes (MSC-exo) supplemented with PPAR-γ agonists (Pioglitazone), which is locally delivered using PLGA nanoparticles (PLGA-exo-PIO) for the treatment of allergic airway diseases using male Balb/c mice.</p> Methods <p>The in vitro and in vivo therapeutic potential was observed using fluorescence imaging, RT-qPCR, ELISA, histopathology, flow cytometry, and bioinformatics analysis.</p> Results <p>Our results indicated that PLGA NPs exhibited prolonged retention and sustained release in the nasal cavity and lungs. In vitro, PLGA-exo-PIO treatment suppresses LPS-induced inflammation in nasal epithelial cells and mast cells. Using murine models of UADs, PLGA-exo-PIO therapy significantly improved the symptom score, reduced inflammatory cells (i.e., eosinophils and goblets) at tissue levels, and upregulated IFN-γ and IL-10 while downregulating histamine, IgE, LTC4, IL-4, and IL-17. In addition, flow cytometric analysis revealed elevated counts of Th1 cells, Tregs, and Bregs, and reduced Th2 cells, eosinophils, and basophils in the blood and spleen of the treated mice. Finally, the data from bioinformatic analysis supported the therapeutic capabilities of fabricated PLGA-exo-PIO via regulation of multiple signaling pathways, such as the Notch cascade and NF-kB cascade.</p> Conclusion <p>For the first time, we used a PLGA-delivered, PIO-strengthened MSC-exo system (PLGA-exo-PIO) as a novel therapy to simultaneously manage AR and asthma as UADs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel pharmaco-exosomal immunotherapy for united airway diseases: PLGA-encapsulated, mesenchymal stem cell-derived exosomes with PPAR-γ agonist for allergic rhinitis and asthma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月2日

查看全文
  • Khawar Ali Shahzad,
  • Zhao Wang,
  • Boyu Cai,
  • Xuran Li,
  • Xiaohui Lv,
  • Yanhong Wang,
  • Fei Tan

摘要

Background

The united airway diseases (UADs), exemplified by allergic rhinitis and asthma, cause significant morbidity. Although conventional pharmacotherapy provides symptomatic relief, recent evidence has indicated that cellular therapy, such as stem cell-derived exosomes, might offer therapeutic advantages throughout the entire respiratory tract.

Objectives

The present study intends to demonstrate the effect and explore the mechanism of a novel pharmaco-exosomal immunotherapy, i.e., mesenchymal stem cells-derived exosomes (MSC-exo) supplemented with PPAR-γ agonists (Pioglitazone), which is locally delivered using PLGA nanoparticles (PLGA-exo-PIO) for the treatment of allergic airway diseases using male Balb/c mice.

Methods

The in vitro and in vivo therapeutic potential was observed using fluorescence imaging, RT-qPCR, ELISA, histopathology, flow cytometry, and bioinformatics analysis.

Results

Our results indicated that PLGA NPs exhibited prolonged retention and sustained release in the nasal cavity and lungs. In vitro, PLGA-exo-PIO treatment suppresses LPS-induced inflammation in nasal epithelial cells and mast cells. Using murine models of UADs, PLGA-exo-PIO therapy significantly improved the symptom score, reduced inflammatory cells (i.e., eosinophils and goblets) at tissue levels, and upregulated IFN-γ and IL-10 while downregulating histamine, IgE, LTC4, IL-4, and IL-17. In addition, flow cytometric analysis revealed elevated counts of Th1 cells, Tregs, and Bregs, and reduced Th2 cells, eosinophils, and basophils in the blood and spleen of the treated mice. Finally, the data from bioinformatic analysis supported the therapeutic capabilities of fabricated PLGA-exo-PIO via regulation of multiple signaling pathways, such as the Notch cascade and NF-kB cascade.

Conclusion

For the first time, we used a PLGA-delivered, PIO-strengthened MSC-exo system (PLGA-exo-PIO) as a novel therapy to simultaneously manage AR and asthma as UADs.